Latest Interviews
Showing 1–9 of 9 transcripts.
Clear all filters- Milken Institute54 min
The Next Era of Health | Global Conference 2026
Esther Krofah, Robert Bradway, Nancy Brown, Alicia Jackson, Myechia Minter-Jordan, Dipen Parekh
Addressing a critical demographic tipping point and a $1 trillion caregiver gap, stakeholders including AARP, ARPA-H, and the American Heart Association are reforming U.S. healthcare to bridge the divide between technological innovation and clinical delivery. Initiatives range from deploying agentic AI to extend cardiovascular prevention to counties lacking specialists, to accelerating long-term care research through new regulatory pathways and a target reduction of drug discovery timelines to under five years. Concurrently, global competition drives a strategic pivot toward genomic integration and value-based models, with specific commitments to reduce Lipoprotein(a) levels by 95% and establish federal tax credits for the nation's 63 million caregivers.
- Milken Institute53 min
Catalyzing Capital, Innovation, and Impact to Advance Women's Health | Global Conference 2026
Esther Krofah, Jill Biden, Diana Ramos, Kalahn Taylor-Clark, Afton Vechery
The Women's Health Network, comprising 170 organizations, launched a $1 billion funding initiative led by Merck's Health Catalytic Fund to address century-old data gaps and the $2 billion annual productivity loss caused by menopause. Driven by strategic partnerships like California's PRIMA screening tool and private sector innovations such as Modern Fertility, the coalition is leveraging artificial intelligence and capital to de-risk early-stage commercialization while targeting a 50% reduction in maternal mortality. This convergence of philanthropic resources and consumer demand aims to shift medical research from male-centric models to comprehensive care for the 51% of the global population that women represent.
- Milken Institute54 min
The Future of Biomedical Research and Innovation | Future of Health Summit 2025
Esther Krofah, Robert Califf, Julie Gerberding, Sharmila Makhija, Elias Zerhouni
A comprehensive review of the U.S. biomedical ecosystem reveals that the nation's seven-pillar research framework is currently threatened by a convergence of reduced federal funding, immigration restrictions, and ideological pressures on universities, all while global competitors like China and Singapore accelerate their own centralized health strategies. Despite possessing a premier research engine, the United States suffers from a critical implementation gap where $5.4 trillion in annual healthcare spending fails to address fundamental issues like low life expectancy, high medical bankruptcy, and a severe erosion of public trust in scientific institutions. Strategic recommendations now urge a shift toward a unified national life sciences strategy that leverages federated data infrastructure, aligns financial incentives with preventive care, and mobilizes political and voter engagement to restore the country's competitive edge in global innovation.
- Milken Institute1h 3m
In Service of a Healthier Tomorrow | Global Conference 2025
Esther Krofah, Gregory Case, Judy Faulkner, Robert Ford, Pablo Legorreta, Ellen Sigal, Greg Case
Leading industry figures including Epic's Judy Faulkner and Aon's Greg Case outline a strategic roadmap for the US healthcare ecosystem to reach 2035, aiming to resolve systemic tensions between biomedical innovation and workforce deficits through widespread AI automation and GLP-1 cost management. The panel identifies critical risks such as proposed 40% cuts to NIH funding, FDA staffing reductions, and regulatory bottlenecks that threaten to undermine US leadership in global life sciences despite breakthroughs like xenotransplantation. Concluding that hope is not a strategy, the consensus calls for immediate cross-sector collaboration to align incentives, secure foundational research funding, and modernize infrastructure to prevent China from seizing global health dominance.
- Milken Institute47 min
Health Innovations to Solve Global Changes | Asia Summit 2023
Esther Krofah, Laurence Lien, Kathryn North, Caroline Riady, Budi Sadikin
No event summary can be generated because the provided text consists of fragmented, corrupted, and incoherent fragments lacking verifiable facts or a logical narrative. The source material oscillates disjointedly between unrelated topics such as healthcare, prison reform, and global politics without establishing substantive connections or clear outcomes. Consequently, the content fails to meet the requirements for a neutral, information-dense description due to its total absence of structural integrity.
- Milken Institute1h 1m
Prevention and Innovation for a Healthier Tomorrow | Global Conference 2024
Esther Krofah, Robert Bradway, David Feinberg, Karen Knudsen, Meena Seshamani
Representatives from CMS, the American Cancer Society, Oracle Health, and Amgen convened to address the U.S. healthcare system's inefficiencies, noting that while the sector consumes 20% of GDP, chronic disease prevalence and administrative friction continue to drive costs while outcomes remain misaligned. Key strategies outlined include shifting Medicare toward value-based care with a $2,000 prescription cap, leveraging AI tools like the Oracle Digital Clinical Assistant to reduce physician administrative burdens, and advocating for federal reimbursement of multi-cancer early detection to improve survival rates. The panelists reached a consensus that the current fragmented structure is impoding and requires fundamental structural reforms rather than incremental solutions to successfully integrate prevention, innovation, and data interoperability.
- Milken Institute1h 16m
Closing Gaps in Health and Health Care | Future of Health Summit 2023
Esther Krofah, AmirAli Talasaz, Susan Barlow, Meg Tirrell, Jaewon Ryu, Ashwin Vasan, Hubertus von Baumbach, Angela F. Williams, Ray Broughan, Bob Cramer, Diane Tai
The 2023 Milken Institute Future of Health Summit convened sector leaders to address the U.S. life expectancy decline and widening inequities despite record spending of over $4.1 trillion annually. Key initiatives announced include the Aging Innovation Collaborative with $3 million in seed funding, New York City's "Healthy NYC" strategy targeting premature death, and a renewed focus on shifting from fee-for-service models to preventive care through public-private partnerships. Experts emphasized that closing the gap requires an industrial health policy to align regulatory updates, leverage AI for early detection, and rebuild community trust through equitable data sharing and resource integration.
- Milken Institute1h 2m
Lessons Learned from COVID-19: Are There Silver Linings for Biomedical Innovation?
Esther Krofah, Francis Collins, Richard Moscicki, Ellen Sigal, Janet Woodcock
Hosted by Faster Cures, a webinar convened NIH officials and industry leaders to analyze the COVID-19 pandemic's acceleration of biomedical innovation, highlighting achievements such as the ACTIV partnership's master protocols and the RADx initiative's diagnostic scaling. The discussion detailed how the crisis forced a shift toward competitive collaboration, decentralized trials, and the successful achievement of diverse vaccine trial enrollment, while simultaneously exposing critical infrastructure gaps in clinical trial execution and real-world data integration. Panelists concluded with a consensus that emergency-driven reforms must be institutionalized through permanent policy changes and public-private partnerships to sustain preparedness for future health threats.
- Milken Institute56 min
Superbugs: Avoiding an Existential Threat to Humanity
Esther Krofah, Valeria Bortolaia, Ron Daniels, Peter Jackson, Peter Piot, Lance Price, Sneha Kemka
This analysis details the critical global escalation of antimicrobial resistance, which currently causes 700,000 annual deaths and threatens to reach 10 million by 2050 without urgent intervention. The event highlights a pharmaceutical market failure where major drug withdrawals have shifted innovation to undercapitalized SMEs, necessitating new economic incentives like the UK's pilot pull mechanism to fund R&D. Strategic solutions prioritize infection control, agricultural bans on growth promoters, and precision diagnostics to bridge the gap between scientific discovery and clinical application.